126 related articles for article (PubMed ID: 37526527)
21. Radioiodine Uptake and Thyroglobulin-Guided Radioiodine Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Prospective, Randomized, Open-Label, Controlled Trial.
Jin Y; Ruan M; Cheng L; Fu H; Liu M; Sheng S; Chen L
Thyroid; 2019 Jan; 29(1):101-110. PubMed ID: 30560716
[TBL] [Abstract][Full Text] [Related]
22. Lithium as an adjuvant in the postoperative ablation of remnant tissue in low-risk thyroid carcinoma.
Yamazaki CA; Padovani RP; Biscolla RP; Ikejiri ES; Marchetti RR; Castiglioni ML; Matsumura LK; Maciel RM; Furlanetto RP
Thyroid; 2012 Oct; 22(10):1002-6. PubMed ID: 22953991
[TBL] [Abstract][Full Text] [Related]
23. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
24. Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels.
Leboulleux S; El Bez I; Borget I; Elleuch M; Déandreis D; Al Ghuzlan A; Chougnet C; Bidault F; Mirghani H; Lumbroso J; Hartl D; Baudin E; Schlumberger M
Thyroid; 2012 Aug; 22(8):832-8. PubMed ID: 22853728
[TBL] [Abstract][Full Text] [Related]
25. Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer.
Torlontano M; Crocetti U; D'Aloiso L; Bonfitto N; Di Giorgio A; Modoni S; Valle G; Frusciante V; Bisceglia M; Filetti S; Schlumberger M; Trischitta V
Eur J Endocrinol; 2003 Jan; 148(1):19-24. PubMed ID: 12534353
[TBL] [Abstract][Full Text] [Related]
26. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study.
Koh JM; Kim ES; Ryu JS; Hong SJ; Kim WB; Shong YK
Clin Endocrinol (Oxf); 2003 Apr; 58(4):421-7. PubMed ID: 12641624
[TBL] [Abstract][Full Text] [Related]
27. Molecular technology and the recombinant TSH have changed diagnostics of thyroid carcinoma with positive I-131 whole body scan but low serum thyroglobulin.
Montella L; Caraglia M; Abbruzzese A; Soricelli A; Prete SD; Squame G; Salvatore M
Exp Mol Med; 2004 Jun; 36(3):268-73. PubMed ID: 15272239
[TBL] [Abstract][Full Text] [Related]
28. Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence.
Rosario PW; Furtado Mde S; Mineiro Filho AF; Lacerda RX; Calsolari MR
Thyroid; 2012 Nov; 22(11):1165-9. PubMed ID: 23050784
[TBL] [Abstract][Full Text] [Related]
29. Predictive Value of Thyroglobulin Changes for the Curative Effect of Radioiodine Therapy in Patients With Metastatic Differentiated Thyroid Carcinoma.
Wang C; Zhang R; Wang R; Meng Z; Zhang G; Dong F; He Y; Tan J
Front Endocrinol (Lausanne); 2021; 12():667544. PubMed ID: 34040584
[TBL] [Abstract][Full Text] [Related]
30. Analysis of radioiodine therapy and prognostic factors of differentiated thyroid cancer patients with pulmonary metastasis: An 8-year retrospective study.
Wang R; Zhang Y; Tan J; Zhang G; Zhang R; Zheng W; He Y
Medicine (Baltimore); 2017 May; 96(19):e6809. PubMed ID: 28489758
[TBL] [Abstract][Full Text] [Related]
31. Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans.
Park EK; Chung JK; Lim IH; Park DJ; Lee DS; Lee MC; Cho BY
Eur J Nucl Med Mol Imaging; 2009 Feb; 36(2):172-9. PubMed ID: 18779963
[TBL] [Abstract][Full Text] [Related]
32. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy.
Torlontano M; Crocetti U; Augello G; D'Aloiso L; Bonfitto N; Varraso A; Dicembrino F; Modoni S; Frusciante V; Di Giorgio A; Bruno R; Filetti S; Trischitta V
J Clin Endocrinol Metab; 2006 Jan; 91(1):60-3. PubMed ID: 16219716
[TBL] [Abstract][Full Text] [Related]
33. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
Lind P; Gallowitsch HJ
Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
[TBL] [Abstract][Full Text] [Related]
34. Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases: including comments on the role of serum thyroglobulin monitoring in tumor surveillance.
Fatourechi V; Hay ID
Semin Nucl Med; 2000 Apr; 30(2):107-14. PubMed ID: 10787191
[TBL] [Abstract][Full Text] [Related]
35. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
[TBL] [Abstract][Full Text] [Related]
36. 99mTc-EDDA/HYNIC-TOC in the diagnosis of differentiated thyroid carcinoma refractory to radioiodine treatment.
Czepczyński R; Gryczyńska M; Ruchała M
Nucl Med Rev Cent East Eur; 2016; 19(2):67-73. PubMed ID: 27479883
[TBL] [Abstract][Full Text] [Related]
37. Compliance with follow-up and the informative value of diagnostic whole-body scan in patients with differentiated thyroid carcinoma given recombinant human TSH.
Cohen O; Dabhi S; Karasik A; Zila Zwas S
Eur J Endocrinol; 2004 Mar; 150(3):285-90. PubMed ID: 15012612
[TBL] [Abstract][Full Text] [Related]
38. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH.
Lippi F; Capezzone M; Angelini F; Taddei D; Molinaro E; Pinchera A; Pacini F
Eur J Endocrinol; 2001 Jan; 144(1):5-11. PubMed ID: 11174831
[TBL] [Abstract][Full Text] [Related]
39. Prediction of treatment response to ¹³¹I therapy by diffuse hepatic uptake intensity on post-therapy whole-body scan in patients with distant metastases of differentiated thyroid cancer.
Jun S; Lee JJ; Park SH; Kim TY; Kim WB; Shong YK; Ryu JS
Ann Nucl Med; 2015 Aug; 29(7):603-12. PubMed ID: 25980591
[TBL] [Abstract][Full Text] [Related]
40. Prognostic implication of thyroglobulin and quantified whole body scan after initial radioiodine therapy on early prediction of ablation and clinical response for the patients with differentiated thyroid cancer.
Lim I; Kim SK; Hwang SS; Kim SW; Chung KW; Kang HS; Lee ES
Ann Nucl Med; 2012 Dec; 26(10):777-86. PubMed ID: 22869417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]